113 related articles for article (PubMed ID: 21351067)
21. Proteomics-based biomarkers in chronic obstructive pulmonary disease.
Chen H; Wang D; Bai C; Wang X
J Proteome Res; 2010 Jun; 9(6):2798-808. PubMed ID: 20387909
[TBL] [Abstract][Full Text] [Related]
22. Factors associated with medication adherence in patients with chronic obstructive pulmonary disease.
Ágh T; Inotai A; Mészáros Á
Respiration; 2011; 82(4):328-34. PubMed ID: 21454953
[TBL] [Abstract][Full Text] [Related]
23. Metalloproteases/anti-metalloproteases imbalance in chronic obstructive pulmonary disease: genetic factors and treatment implications.
Mocchegiani E; Giacconi R; Costarelli L
Curr Opin Pulm Med; 2011 Dec; 17 Suppl 1():S11-9. PubMed ID: 22209925
[TBL] [Abstract][Full Text] [Related]
24. Decline in FEV1 related to genetic polymorphisms (+138insA/delA and Lys198Asn) of the endothelin-1 gene in COPD. A pilot study.
Kaparianos A; Argyropoulou E; Efremidis G; Flordellis C; Spiropoulos K
Eur Rev Med Pharmacol Sci; 2010 Aug; 14(8):705-19. PubMed ID: 20707291
[TBL] [Abstract][Full Text] [Related]
25. Exhaled nitric oxide measure using multiple flows in clinically relevant subgroups of COPD.
Bazeghi N; Gerds TA; Budtz-Jørgensen E; Hove J; Vestbo J
Respir Med; 2011 Sep; 105(9):1338-44. PubMed ID: 21530214
[TBL] [Abstract][Full Text] [Related]
26. It's about time--directing our attention toward modifying the course of COPD.
Cazzola M; Hanania NA; Jones PW; Mahler DA; Make B; Ohar J; Rennard S
Respir Med; 2008 Jun; 102 Suppl 1():S37-48. PubMed ID: 18582796
[TBL] [Abstract][Full Text] [Related]
27. Practical management problems of stable chronic obstructive pulmonary disease in the elderly.
Pistelli R; Ferrara L; Misuraca C; Bustacchini S
Curr Opin Pulm Med; 2011 Dec; 17 Suppl 1():S43-8. PubMed ID: 22209930
[TBL] [Abstract][Full Text] [Related]
28. Pathogenesis of COPD.
Spurzem JR; Rennard SI
Semin Respir Crit Care Med; 2005 Apr; 26(2):142-53. PubMed ID: 16088433
[TBL] [Abstract][Full Text] [Related]
29. Inspiratory capacity and forced expiratory volume in the first second in exacerbation of chronic obstructive pulmonary disease.
Yetkin O; Gunen H
Clin Respir J; 2008 Jan; 2(1):36-40. PubMed ID: 20298302
[TBL] [Abstract][Full Text] [Related]
30. C-reactive protein and copeptin: prognostic predictors in chronic obstructive pulmonary disease exacerbations.
Antonescu-Turcu AL; Tomic R
Curr Opin Pulm Med; 2009 Mar; 15(2):120-5. PubMed ID: 19532026
[TBL] [Abstract][Full Text] [Related]
31. Circulating vascular endothelial growth factor and systemic inflammatory markers in patients with stable and exacerbated chronic obstructive pulmonary disease.
Valipour A; Schreder M; Wolzt M; Saliba S; Kapiotis S; Eickhoff P; Burghuber OC
Clin Sci (Lond); 2008 Oct; 115(7):225-32. PubMed ID: 18307413
[TBL] [Abstract][Full Text] [Related]
32. Sex hormone alterations and systemic inflammation in a group of male COPD smokers and their correlation with the +138 insA/delA endothelin-1 gene polymorphism. A case-control study.
Kaparianos A; Argyropoulou E; Efremidis G; Spiropoulos K
Eur Rev Med Pharmacol Sci; 2011 Oct; 15(10):1149-57. PubMed ID: 22165675
[TBL] [Abstract][Full Text] [Related]
33. Complement factor C5a in acute exacerbation of Chronic Obstructive Pulmonary Disease.
Marc MM; Kristan SS; Rozman A; Kern I; Flezar M; Kosnik M; Korosec P
Scand J Immunol; 2010 May; 71(5):386-91. PubMed ID: 20500690
[TBL] [Abstract][Full Text] [Related]
34. Identification of distinct plasma biomarker signatures in patients with rapid and slow declining forms of COPD.
Devanarayan V; Scholand MB; Hoidal J; Leppert MF; Crackower MA; O'Neill GP; Gervais FG
COPD; 2010 Feb; 7(1):51-8. PubMed ID: 20214463
[TBL] [Abstract][Full Text] [Related]
35. Frequent chronic obstructive pulmonary disease exacerbators: how much real, how much fictitious?
Soler-Cataluña JJ; Rodriguez-Roisin R
COPD; 2010 Aug; 7(4):276-84. PubMed ID: 20673037
[TBL] [Abstract][Full Text] [Related]
36. Personalizing and targeting therapy for COPD: the role of molecular and clinical biomarkers.
Goh F; Shaw JG; Savarimuthu Francis SM; Vaughan A; Morrison L; Relan V; Marshall HM; Dent AG; O'Hare PE; Hsiao A; Bowman RV; Fong KM; Yang IA
Expert Rev Respir Med; 2013 Dec; 7(6):593-605. PubMed ID: 24160750
[TBL] [Abstract][Full Text] [Related]
37. A hypothesis to phenotype COPD exacerbations by aetiology.
MacDonald M; Beasley RW; Irving L; Bardin PG
Respirology; 2011 Feb; 16(2):264-8. PubMed ID: 21272142
[TBL] [Abstract][Full Text] [Related]
38. Developing and applying a stochastic dynamic population model for chronic obstructive pulmonary disease.
Hoogendoorn M; Rutten-van Mölken MP; Hoogenveen RT; Al MJ; Feenstra TL
Value Health; 2011 Dec; 14(8):1039-47. PubMed ID: 22152172
[TBL] [Abstract][Full Text] [Related]
39. Increased DNA damage in patients with chronic obstructive pulmonary disease who had once smoked or been exposed to biomass.
Ceylan E; Kocyigit A; Gencer M; Aksoy N; Selek S
Respir Med; 2006 Jul; 100(7):1270-6. PubMed ID: 16307872
[TBL] [Abstract][Full Text] [Related]
40. Decreased histone deacetylase activity in chronic obstructive pulmonary disease.
Ito K; Ito M; Elliott WM; Cosio B; Caramori G; Kon OM; Barczyk A; Hayashi S; Adcock IM; Hogg JC; Barnes PJ
N Engl J Med; 2005 May; 352(19):1967-76. PubMed ID: 15888697
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
